Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.
Status:
Completed
Trial end date:
2011-12-16
Target enrollment:
Participant gender:
Summary
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
developed for the treatment of chronic obstructive pulmonary disease (COPD). The long
duration of action of GSK573719, when administered via inhalation to humans supports the
potential for use as a long acting bronchodilator.This is a randomized, double-blind,
placebo-controlled, 5 period cross-over study in healthy male and female volunteers. The
study will measure lung function after single inhaled doses from two configurations of the
Novel Dry Powder Inhaler. Key assessments will include clinical relevant PD parameters: sGaw,
FEV1